Literature DB >> 12654610

L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells.

Zhijun Ou1, Jingsong Ou, Allan W Ackerman, Keith T Oldham, Kirkwood A Pritchard.   

Abstract

BACKGROUND: Low-density lipoprotein (LDL) impairs endothelial cell function by uncoupling endothelial nitric oxide synthase (eNOS) activity, which allows superoxide anion (O2*-)) to be generated rather than nitric oxide (*NO). Recent reports indicate that apolipoprotein (apo) A-1 mimetics inhibit the development of atherosclerotic lesions in LDL receptor-null mice. Here we hypothesize that L-4F, an apoA-1 mimetic that inhibits atherosclerosis induced by hypercholesterolemia, protects endothelial cell function by preventing LDL from uncoupling eNOS activity. METHODS AND
RESULTS: Bovine aortic endothelial cells were incubated with LDL+/-L-4F, and changes in A23187-stimulated.NO and O2*- generation were determined by ozone chemiluminescence and superoxide dismutase-inhibitable ferricytochrome c reduction, respectively. Western analysis of eNOS immunoprecipitates was used to determine effects of LDL and L-4F on heat shock protein 90 (hsp90) interactions with eNOS. LDL decreased.NO production and increased eNOS-dependent O2*- generation. Pretreatment of LDL with L-4F increased.NO and decreased O2*- generation. By itself, L-4F had no effect on O2*- but did increase *NO generation. Stimulation of endothelial cells incubated with LDL decreased the association of hsp90 with eNOS. Pretreatment of LDL with L-4F prevented a decrease in hsp90 association with eNOS and often enhanced association on stimulation.
CONCLUSIONS: These data demonstrate that L-4F protects endothelial cell function by preventing LDL from uncoupling eNOS activity. L-4F allows endothelial cell to maintain coupled eNOS activity to generate.NO even in the face of atherogenic concentrations of LDL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654610     DOI: 10.1161/01.cir.0000061949.17174.b6

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Authors:  Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Shaila P Handattu; Vinod K Mishra; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-06-23       Impact factor: 5.162

Review 2.  Reactive oxygen species and redox-regulation of skeletal muscle adaptations to exercise.

Authors:  Malcolm J Jackson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

Review 3.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

4.  Time-course changes of nLDL-induced erectile dysfunction.

Authors:  N Durmus; A Toylu; S Evcim; B C Soner; O Demir; E Kahraman; T Demir; B Irer; S Gidener; N Atabey; A Esen
Journal:  Int J Impot Res       Date:  2017-03-16       Impact factor: 2.896

5.  Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.

Authors:  Gaurav Nayyar; Vinod K Mishra; Shaila P Handattu; Mayakonda N Palgunachari; Ronald Shin; David T McPherson; Champion C S Deivanayagam; David W Garber; Jere P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2012-02-29       Impact factor: 5.922

6.  The preventive effects of apolipoprotein mimetic D-4F from vibration injury-experiment in rats.

Authors:  David J Rowe; Ji-Geng Yan; Lin Ling Zhang; Kirkwood A Pritchard; Dennis S Kao; Hani S Matloub; Danny A Riley
Journal:  Hand (N Y)       Date:  2010-09-08

7.  Cumulative Brain Injury from Motor Vehicle-Induced Whole-Body Vibration and Prevention by Human Apolipoprotein A-I Molecule Mimetic (4F) Peptide (an Apo A-I Mimetic).

Authors:  Ji-Geng Yan; Lin-ling Zhang; Michael Agresti; Yuhui Yan; John LoGiudice; James R Sanger; Hani S Matloub; Kirkwood A Pritchard; Safwan S Jaradeh; Robert Havlik
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-12       Impact factor: 2.136

8.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

Review 9.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

10.  The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice.

Authors:  Stephen J Peterson; Dong Hyun Kim; Ming Li; Vincenzo Positano; Luca Vanella; Luigi F Rodella; Francesco Piccolomini; Nitin Puri; Amalia Gastaldelli; Claudia Kusmic; Antonio L'Abbate; Nader G Abraham
Journal:  J Lipid Res       Date:  2009-02-17       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.